Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain zaps may boost memory in schizophrenia patients

NCT ID NCT01545999

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a brain stimulation technique called paired associative stimulation (PAS) using transcranial magnetic stimulation (TMS) in 72 adults with schizophrenia. The goal is to see if daily sessions over two weeks can improve working memory, as measured by a letter-matching task. Researchers will also use EEG to track brain activity changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcranial Magnetic Stimulation (TMS)
What this could lead to
If successful, this could point toward a non-drug treatment to improve memory and thinking in people with schizophrenia.
What could go wrong
This is an early-stage study with only 72 participants, and it is not testing a cure. The effects may be small or not last long, and the treatment requires daily sessions for two weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2012

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients: * Age 18 or above * All races and ethnicities. * Females and males. * Meet DSM-IV TR criteria for a current diagnosis of schizophrenia or schizoaffective disorder. * Clinically stable as operationalized by (1) either having not been hospitalized within 3 months or having been hospitalized for 3 months or more prior to assessment, and (2) having had no change in antipsychotic medication dosage within the 4 weeks prior to assessment. * Willingness and ability to speak English * Willingness to provide informed consent * Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice. Exclusion Criteria for patients: * Meets criteria for a cognitive disorder secondary to a neurological or other medical disorder affecting the central nervous system (for example, multiple sclerosis, history of traumatic brain injury, stroke, untreated hypothyroidism). * Mini Mental Status Examination score of 17 and less because a subject with a very low MMSE score is unlikely to be able to compete the NP battery. * Diagnosis of bipolar disorder or current major depressive episode. * Meets diagnostic criteria for current alcohol or other drug dependence within 6 months of testing * Electroconvulsive Therapy (ECT) within 6 months of testing. * Left handedness. * Incompetency to consent Inclusion Criteria for controls: * Age 18 or above * Willingness and ability to speak English * Willingness to provide informed consent * Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice. Exclusion Criteria for controls: * DSM IV TR psychiatric diagnosis except for simple phobias or an adjustment disorder. * Other neurological disorder affecting central nervous system. * Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks. * Family history of a primary psychotic disorder in a first-degree relative. * Left handedness.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    Toronto, Ontario, M6J 1H4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.